| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Y-mAbs Therapeutics Inc (NASDAQ: YMAB)
YMAB Technical Analysis
4
| As on 9th Jun 2023 YMAB STOCK Price closed @ 8.17 and we RECOMMEND Sell for LONG-TERM with Stoploss of 12.48 & Strong Sell for SHORT-TERM with Stoploss of 11.35 we also expect STOCK to react on Following IMPORTANT LEVELS. |
YMABSTOCK Price
| Open | 8.23 | Change | Price | % |
| High | 8.66 | 1 Day | 0.04 | 0.49 |
| Low | 8.00 | 1 Week | -0.53 | -6.09 |
| Close | 8.17 | 1 Month | 2.39 | 41.35 |
| Volume | 253176 | 1 Year | -7.98 | -49.41 |
| 52 Week High 19.67 | 52 Week Low 2.83 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| YMAB Daily Charts |
YMAB Intraday Charts |
Whats New @ Bazaartrend |
YMAB Free Analysis |
|
|
YMAB Important Levels Intraday
| RESISTANCE | 9.44 |
| RESISTANCE | 9.03 |
| RESISTANCE | 8.78 |
| RESISTANCE | 8.53 |
| SUPPORT | 7.81 |
| SUPPORT | 7.56 |
| SUPPORT | 7.31 |
| SUPPORT | 6.90 |
YMAB Forecast May 2024
| 4th UP Forecast | 28.02 |
| 3rd UP Forecast | 21.65 |
| 2nd UP Forecast | 17.72 |
| 1st UP Forecast | 13.78 |
| 1st DOWN Forecast | 2.56 |
| 2nd DOWN Forecast | -1.38 |
| 3rd DOWN Forecast | -5.31 |
| 4th DOWN Forecast | -11.68 |
YMAB Weekly Forecast
| 4th UP Forecast | 11.95 |
| 3rd UP Forecast | 10.74 |
| 2nd UP Forecast | 9.99 |
| 1st UP Forecast | 9.24 |
| 1st DOWN Forecast | 7.10 |
| 2nd DOWN Forecast | 6.35 |
| 3rd DOWN Forecast | 5.60 |
| 4th DOWN Forecast | 4.39 |
YMAB Forecast2024
| 4th UP Forecast | 42.43 |
| 3rd UP Forecast | 31.44 |
| 2nd UP Forecast | 24.65 |
| 1st UP Forecast | 17.86 |
| 1st DOWN Forecast | -1.52 |
| 2nd DOWN Forecast | -8.31 |
| 3rd DOWN Forecast | -15.1 |
| 4th DOWN Forecast | -26.09 |
Y-mAbs Therapeutics Inc ( NASDAQ USA Symbol : YMAB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
YMAB Business Profile
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Address: 230 Park Avenue, New York, NY, United States, 10169
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service